GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA - Analyst Blog

By
A A A

GlaxoSmithKline ( GSK ) received positive news when the FDA approved its asthma treatment, Arnuity Ellipta.

Arnuity Ellipta has been approved in doses of 100 mcg and 200 mcg as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and above. Glaxo had evaluated the efficacy and safety of Arnuity Ellipta in more than 3,600 patients suffering from asthma.

The approval of Arnuity Ellipta should relieve Glaxo as its respiratory product portfolio has been facing challenges of late. Meanwhile, Glaxo's plans to transition and diversify its respiratory portfolio are underway. The transition is expected to continue over the next 2-3 years.

During the second quarter of 2014, Glaxo filed Breo for approval in the U.S. for asthma. In Jul 2014, Glaxo initiated a phase III study, IMPACT, to evaluate the efficacy and safety of the triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD). Glaxo also plans to file its first biologic, mepolizumab, for severe asthma by the end of 2014.

Increasing competition and pricing pressure has adversely impacted Glaxo's results in recent times. The company expects new products such as Breo, Anoro and Incruse, along with expected approvals to drive sales in the coming quarters. We cautiously watch Glaxo's plans to transform its lagging respiratory business.

Glaxo carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the healthcare sector include Allergan ( AGN ), AstraZeneca ( AZN ), and AbbVie ( ABBV ). While Allergan sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , AGN , GSK , ABBV

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

75,031,044
  • $16.26 ▲ 0.31%
64,683,841
  • $99.76 ▲ 2.14%
44,561,744
  • $14 ▼ 6.23%
37,984,130
  • $27.93 ▲ 0.36%
36,148,020
  • $94.39 ▲ 1.49%
33,981,456
  • $22.93 ▼ 1.38%
33,971,527
  • $44.08 ▲ 1.03%
33,685,322
  • $76.95 ▲ 1.32%
As of 10/20/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com